Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  T.ACB.WS.U | ACB

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution, and sale of cannabis related products in Canada and internationally. The Company’s segments include Canadian Cannabis, European Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol and CraftPlant. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia, and Odense, Denmark. The Company is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets.


TSX:ACB - Post by User

Bullboard Posts
Comment by Slothman2on Sep 24, 2018 8:10pm
304 Views
Post# 28681852

RE:Quotes from earnings report...........

RE:Quotes from earnings report...........
insidersnoop1 wrote:Cash Position, Cash Flows, and Working Capital

Net cash and cash equivalents on hand decreased from $159.7 million at the end of Q4 2017 to $89.2 million as at Q4 2018. "



LOST 5% OF PATIENTS IN LAST QUARTER ?

Active registered patients   

43,308

   45,776

   (5%)



DYODD


The number of active registered patients increased to 43,308, up from 16,400.

The cash cost for dried cannabis sold was $1.87 per gram, down from $2.09 a year earlier.

The cash cost to produce dried cannabis also decreased 11 per cent, to $1.70 per gram, from $1.91. The decrease was primarily due to efficiencies from automation and yield expertise.

Net income attributable to shareholders was nearly $80 million, up from a $4.82 million loss a year ago.


For the full year, revenues increased to $55.2 million from $18.1 million in 2017.

seeing its revenues more than triple to $19.1 million in the fourth quarter.

stfu you desperate $kank


Bullboard Posts